Cargando…
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
We present a case of a 59-year-old male with a confirmed diagnosis of small-cell lung cancer (SCLC). He had progressive disease even after four cycles of cisplatin and etoposide chemotherapy and 21 cycles of radiation. He was therefore started on immunotherapy with nivolumab every 2 weeks and ipilim...
Autores principales: | Agrawal, Kavita, Agrawal, Nirav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633879/ https://www.ncbi.nlm.nih.gov/pubmed/31355029 http://dx.doi.org/10.1155/2019/5353202 |
Ejemplares similares
-
Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome
por: Bukhari, Sumera, et al.
Publicado: (2017) -
Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2018) -
Lambert-Eaton Myasthenic Syndrome in Lung Cancer
por: Wang, Yongbin, et al.
Publicado: (2022) -
Amifampridine for Lambert-Eaton myasthenic syndrome
Publicado: (2022) -
Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
por: Machiyama, Hirotomo, et al.
Publicado: (2023)